查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1797896

全球泛自闭症障碍诊断市场：预测至 2032 年—按类型、诊断方法、服务、年龄层、分销管道、最终用户和地区进行分析

Autism Spectrum Disorder Diagnostics Market Forecasts to 2032 - Global Analysis By Type, Diagnostic Method, Service, Age Group, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球泛自闭症障碍诊断市场预计在 2025 年达到 299.9 亿美元，预计到 2032 年将达到 566.1 亿美元，预测期内的复合年增长率为 9.5%。

自闭症频谱(ASD) 的诊断需要经过全面的评估，包括发展筛检和深入评估，由心理学家、神经科和发育小儿科等专家进行。诊断过程的目标是识别限制性和重复性行为、兴趣和活动的模式，以及社交沟通和互动方面的持续挑战。这些症状应该从幼儿时期就已存在，儘管它们可能在社交需求超出个人能力之前不会完全被察觉。临床医生会使用标准化测量方法，例如自闭症诊断观察量表和自闭症诊断访谈修订版，并结合来自父母、教育工作者和看护者的回馈。

根据美国疾病管制与美国中心自闭症和发展障碍监测 (ADDM) 网路的数据，2022 年，每 31 名 8 岁儿童中就有 1 名（约 3.2%）被诊断为泛自闭症障碍(ASD)。

提高对自闭症的认识和盛行率

推动诊断市场发展的关键因素之一是全球泛自闭症障碍诊断数量的不断增长。这一增长源于筛检程序的改进、诊断标准的拓宽、社会和临床认知的提升，以及实际病例数的增加。社区组织、医疗保健系统和学校对早期征兆识别能力的提高，也促进了转诊评估的增加。此外，儘管自闭症谱系障碍（ASD）过去相对容易被误解，但如今许多国家已将自闭症谱系障碍筛检作为儿童发展计画的一部分，从而显着扩展了诊断服务和工具的市场。

训练有素的专业人员短缺和服务缺口

诊断自闭症谱系障碍 (ASD) 面临的最大挑战之一是缺乏熟练的专家，例如发育小儿科、儿童心理学家、神经科和语言病理学家。诊断过程需要大量的培训和跨学科合作，而这在新兴国家和农村地区尤其匮乏。因此，家庭往往需要等待数月甚至数年，导致诊断和早期疗育服务延迟。都市区通常拥有更多的资源和专家，这导致获得医疗服务的机会有显着差异。诊断速度和品质的地区差异，加上专业知识分布不均，限制了整体市场的成长。

基因和生物标记研究进展

持续进行的自闭症生物学病因研究发现了一些颇具前景的基因标记、神经影像模式和生化指标，这些指标有可能彻底改变自闭症的诊断方法。基于生物标记的检测提供了可扩展、早期且客观的筛检技术，或许可以补充甚至超越行为评估。随着对自闭症病因的科学认识不断进步，诊断技术将得到改进，从而能够识别不同的自闭症亚型，从而实现更专业的干预方法。这将提高诊断的准确性和可靠性，并为自闭症治疗的个人化医疗策略铺平道路。

资料隐私和道德问题

许多新的诊断技术，尤其是那些使用人工智慧、行动应用程式和远端保健平台的技术，都需要收集敏感的个人和行为数据，这些数据通常来自儿童。这些技术引发了严重的隐私、知情同意和资料保护问题，尤其是在美国《健康保险互通性与课责法案》（HIPAA）和欧盟《一般资料保护规则》（GDPR）等法律严格的司法管辖区。违反保密规定、滥用非医疗资料以及资料所有权不明确可能会损害公众信任，并阻碍新诊断技术的采用。未能实施强而有力的安全措施和开放隐私权政策的公司不仅可能面临声誉受损的风险，还可能面临法律后果。

COVID-19的影响：

新冠疫情泛自闭症障碍(ASD) 诊断市场产生了多方面的影响。最初，封锁、诊所关闭以及对面对面评估的限制导致服务中断，导致全球范围内的诊断延误和漫长的等待时间。安全隐患和专家就诊管道受限导致许多家庭延迟诊断，尤其是在医疗资源匮乏的农村地区。然而，这场危机也推动了基于人工智慧的评估、筛检工具和虚拟行为观察的进步，以及远距远端医疗和远距离诊断解决方案的快速普及。最终，虽然短期收益受到影响，但疫情透过将远距离诊断纳入标准诊疗，提高了特定人群的可近性，并在市场中创造了新的成长机会，引发了长期变革。

行为评估部分预计将成为预测期内最大的部分

预计行为评估领域将在预测期内占据最大的市场占有率。这些测试是诊断自闭症谱系障碍 (ASD) 的基础，因为它们专注于仔细观察患者的社交互动、沟通技巧和重复行为——所有这些都是自闭症的关键指标。为了进行全面评估，世界各地的临床医生经常使用标准化工具，例如自闭症诊断观察量表 (ADOS) 和自闭症诊断访谈修订版 (ADI-R)，并经常结合看护者的意见。这些工具因其非侵入性、价格实惠且适用于广泛年龄层而广受欢迎。此外，行为评估与教育和医疗保健系统紧密结合，使其易于用于早期筛检和早期疗育。

预计数位评估工具领域在预测期内将实现最高复合年增长率

预计数位评估工具领域将在预测期内实现最高成长率。这得益于基于云端和人工智慧的App平台的快速普及，这些平台能够实现对自闭症相关行为的远端、可扩展和早期筛检。这些工具价格实惠，并且能快速洞察，非常适合诊所、学校和家庭使用。智慧型手机普及率的提高、数位素养的提高以及远端医疗，进一步推动了这些工具的普及。此外，数位评估工具正在彻底改变自闭症谱系障碍（ASD）的诊断方式，凭藉其实时数据分析、与医疗保健系统的互通性以及用户友好介面的优势，巩固了其作为全球成长最快市场的地位。

比最大的地区

预计北美将在预测期内占据最大的市场占有率，这得益于标准化诊断方法的广泛应用、较高的认知度以及先进的医疗基础设施。该地区受益于ASD评估和干预的保险覆盖范围扩大，以及强有力的政府和非营利项目鼓励早期筛检。其市场主导地位因能够接触到顶级诊断公司、高素质临床专业人员以及基因检测和基于人工智慧的筛检工具等最尖端科技而得到进一步加强。此外，北美是全球ASD诊断的中心，这归因于多种因素，包括自闭症盛行率的不断上升、大量的研究资金以及医疗保健组织和学术机构之间的强有力伙伴关係。

复合年增长率最高的地区：

预计亚太地区将在预测期内实现最高的复合年增长率，这得益于政府早期筛检和早期疗育项目的增加、医疗基础设施的改善以及自闭症意识的不断提升。农村和半都市区医疗服务可近性的改善正在扩大患者群体，而中国、印度和日本等国家的快速经济成长也推动了对诊断技术的投资增加。远端医疗服务和数位评估工具的日益普及，使得诊断更便宜、方便。此外，国际诊断公司与本地医疗服务提供者之间的合作、盛行率的上升以及教育普及率的活性化也推动了该地区市场的成长。

免费客製化服务

此报告的订阅者可以从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 介绍
  • 驱动程式
  • 抑制因素
  • 市场机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球泛自闭症障碍诊断市场（按类型）

  • 自闭症
  • 亚斯伯格症候群
  • 广泛性发展障碍（PDD）
  • 其他类型
    • 非典型自闭症
    • 儿童崩坏障碍
    • PDD-NOS

6. 全球泛自闭症障碍诊断市场（依诊断方法）

  • 行为评估
  • 基因检测
  • 神经影像技术
  • 生物标记分析
  • 发育筛检
  • 认知评估
  • 神经系统评估

7. 全球泛自闭症障碍诊断市场（按服务）

  • 临床评估
  • 标准化筛检工具
  • 数位评估工具
  • 神经心理学测试
  • 行为方法
  • 早期疗育
  • 药物治疗
  • 远端医疗服务
  • 其他服务

8. 全球泛自闭症障碍诊断市场（依年龄层）

  • 孩子们
  • 青年
  • 成人

9. 全球泛自闭症障碍诊断市场（按通路）

  • 医院药房
  • 药局和药房
  • 网路药局

第 10 章。全球泛自闭症障碍诊断市场（按最终用户）

  • 医院
  • 诊断中心
  • 研究所
  • 专科诊所
  • 教育机构

11. 全球泛自闭症障碍诊断市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • Agilent Technologies Inc.
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Cognoa Inc.
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers
  • Invitae Corporation
  • GE Healthcare
  • Illumina, Inc.
  • GeneDx
  • PerkinElmer, Inc.
  • Fulgent Genetics
  • Charles River Laboratories International, Inc.
  • Myriad Genetics, Inc.
  • Cortica Inc.
Product Code: SMRC30266

According to Stratistics MRC, the Global Autism Spectrum Disorder Diagnostics Market is accounted for $29.99 billion in 2025 and is expected to reach $56.61 billion by 2032 growing at a CAGR of 9.5% during the forecast period. Autism Spectrum Disorder (ASD) is diagnosed through a comprehensive evaluation that typically involves developmental screening and a detailed assessment by specialists such as psychologists, neurologists, or developmental pediatricians. The goal of the diagnostic process is to find limited, repetitive patterns of behavior, interests, or activities as well as ongoing challenges with social communication and interaction. Although these symptoms may not be completely noticeable until social demands surpass the person's capacity, they must be present from an early age. Together with feedback from parents, educators, and caregivers, clinicians utilize standardized instruments such as the Autism Diagnostic Observation Schedule and the Autism Diagnostic Interview-Revised.

According to data from the U.S. Centers for Disease Control and Prevention's Autism and Developmental Disabilities Monitoring (ADDM) Network, about 1 in 31 eight-year-old children-approximately 3.2%-were identified with Autism Spectrum Disorder (ASD) in 2022.

Market Dynamics:

Driver:

Growing awareness and prevalence of ASD

One of the main factors propelling the diagnostics market is the increase in diagnoses of autism spectrum disorder worldwide. This growth is a result of improved screening procedures, expanded diagnostic criteria, and increased public and clinical awareness in addition to an actual rise in cases. More referrals for evaluation result from improved early sign recognition by community organizations, healthcare systems, and schools. Furthermore, the market for diagnostic services and tools has grown dramatically as ASD is now actively screened for as part of child development programs in many countries, having previously been a relatively misunderstood condition.

Restraint:

Shortage of trained specialists and service disparities

One of the most important issues in diagnosing ASD is the lack of skilled specialists, such as developmental pediatricians, child psychologists, neurologists, and speech-language pathologists. The diagnostic process necessitates extensive training and interdisciplinary collaboration, but there is a shortage of these specialists, particularly in developing countries and rural areas. Families are consequently frequently faced with lengthy waiting lists, which can last for months or even years. This causes a delay in diagnosis and early intervention services. Because urban areas typically have more resources and specialists, there are glaring differences in the availability of care. Regional disparities in the promptness and quality of diagnosis are exacerbated by the unequal distribution of expertise, which restricts the growth of the entire market.

Opportunity:

Developments in genetic and biomarker research

Promising genetic markers, neuroimaging patterns, and biochemical indicators that have been found through ongoing research into the biological causes of autism have the potential to completely transform diagnostics. Tests based on biomarkers may offer scalable, early, and objective screening techniques that supplement or even outperform behavioral evaluations. Diagnostic techniques can be improved to identify distinct subtypes of autism as scientific knowledge of the etiology of ASD grows, allowing for more specialized intervention approaches. This improves diagnosis precision and dependability while also paving the way for personalized medicine strategies in the treatment of ASD.

Threat:

Concerns about data privacy and ethics

The gathering of sensitive personal and behavioral data, frequently from children, is necessary for many new diagnostic technologies, especially those that use AI, mobile apps, and telehealth platforms. Particularly in areas with stringent laws like the US Health Insurance Portability and Accountability Act (HIPAA) or the EU's General Data Protection Regulation (GDPR), this presents serious questions regarding privacy, consent, and data protection. Confidentiality violations, non-medical data misuse, or ambiguous data ownership could erode public confidence and discourage the use of novel diagnostic techniques. Businesses that neglect to put strong security measures and open privacy policies in place risk legal repercussions as well as harm to their reputation.

Covid-19 Impact:

The COVID-19 pandemic had a mixed effect on the market for diagnostics for autism spectrum disorder (ASD). At first, lockdowns, clinic closures, and limitations on in-person evaluations caused service disruptions, which resulted in delayed diagnoses and long waiting lists globally. Due to safety concerns or limited access to specialists, many families delayed assessments, especially in underserved and rural areas. But the crisis also spurred advancements in AI-based evaluations, digital screening tools, and virtual behavioural observations, as well as a faster uptake of telehealth and remote diagnostic solutions. The pandemic eventually sparked long-term changes by incorporating remote diagnostics into standard practice, improving accessibility for certain populations, and creating new growth opportunities for the market, even though short-term revenues suffered.

The behavioral assessments segment is expected to be the largest during the forecast period

The behavioral assessments segment is expected to account for the largest market share during the forecast period. These tests serve as the foundation for diagnosing ASD because they concentrate on closely observing a person's social interactions, communication abilities, and repetitive behaviors-all of which are key markers of autism. To ensure thorough evaluation, clinicians around the world frequently use standardized tools like the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R), frequently in conjunction with caregiver input. They are very popular because of their non-invasiveness, affordability, and suitability for a range of age groups. Furthermore, behavioral assessments are easily accessible for early screening and intervention because they are intricately woven into the educational and healthcare systems.

The digital assessment tools segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the digital assessment tools segment is predicted to witness the highest growth rate, driven by the quick uptake of cloud-enabled, AI-powered, app-based platforms that allow for remote, scalable, and early screening of behaviors linked to autism. These tools are perfect for use in clinics, schools, and homes because they are affordable, accessible, and provide fast insights. Their adoption has been further accelerated by growing smart phone penetration, rising digital literacy, and the post-pandemic acceptance of telehealth. Moreover, digital assessment tools are revolutionizing ASD diagnostics and establishing themselves as the fastest-growing market in the world by combining real-time data analytics, interoperability with healthcare systems, and user-friendly interfaces.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by widespread adoption of standardized diagnostic procedures, high awareness levels, and sophisticated healthcare infrastructure. The area benefits from substantial insurance coverage for ASD assessments and interventions, as well as robust governmental and nonprofit programs encouraging early screening. Its market dominance is further reinforced by the presence of top diagnostic companies, highly qualified clinical professionals, and access to cutting-edge technologies like genetic testing and AI-based screening tools. Additionally, North America is the world's leading center for ASD diagnostics due to a number of factors, including growing autism prevalence rates, substantial research funding, and solid partnerships between healthcare organizations and academic institutions.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by increased government programs for early screening and intervention, better healthcare infrastructure, and growing awareness of autism. While increasing access to healthcare in rural and semi-urban areas is expanding the patient base, rapid economic growth in nations like China, India, and Japan has resulted in increased investments in diagnostic technologies. Diagnostics are becoming more affordable and accessible due to the growing use of telehealth services and digital assessment tools. Furthermore, the accelerated market growth in this region is also being driven by partnerships between international diagnostic companies and regional healthcare providers, rising prevalence rates, and increased educational outreach.

Key players in the market

Some of the key players in Autism Spectrum Disorder Diagnostics Market include Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Cognoa Inc., Thermo Fisher Scientific Inc., Siemens Healthineers, Invitae Corporation, GE Healthcare, Illumina, Inc., GeneDx, PerkinElmer, Inc., Fulgent Genetics, Charles River Laboratories International, Inc., Myriad Genetics, Inc. and Cortica Inc.

Key Developments:

In July 2025, Agilent Technologies Inc. announced the recent signing of a Memorandum of Understanding (MOU) with the Nanyang Environment & Water Research Institute, outlining their collaboration in advancing environmental and water research over the next three years. NEWRI is a leading research institute at Nanyang Technological University, Singapore, ranked 13th globally for Environmental Sciences by QS World University Ranking in 2025.

In March 2025, F. Hoffmann-LaRoche Ltd and Danish Zealand Pharma A/S have entered into a license agreement to co-develop and co-commercialise Zealand's Phase II long-acting amylin mimetic petrelintide in weight management of overweigt and obese people. Besides petrelintide monotherapy, Zealand will also help co-develop and co-commercialise drug combos such as petrelintide/CT-388, which Roche got in 2023 from the acquisition of Carmot Therapeutics, in the US and Europe.

In December 2024, Abbott Laboratories and DexCom that they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices. The agreement will dismiss all pending cases in courts and patent offices worldwide, along with a provision preventing legal action between the companies for patent and appearance disputes for the next 10 years.

Types Covered:

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Development Disorder (PDD)
  • Other Types

Diagnostic Methods Covered:

  • Behavioral Assessments
  • Genetic Testing
  • Neuroimaging Techniques
  • Biomarker Analysis
  • Developmental Screening
  • Cognitive Assessment
  • Neurological Assessment

Services Covered:

  • Clinical Assessments
  • Standardized Screening Tools
  • Digital Assessment Tools
  • Neuropsychological Tests
  • Behavioral Approaches
  • Early Intervention
  • Medication
  • Telehealth Services
  • Other Services

Age Groups Covered:

  • Children (Pediatric)
  • Adolescents
  • Adults

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Research Institutes
  • Specialty Clinics
  • Educational Institutions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autism Spectrum Disorder Diagnostics Market, By Type

  • 5.1 Introduction
  • 5.2 Autistic Disorder
  • 5.3 Asperger Syndrome
  • 5.4 Pervasive Development Disorder (PDD)
  • 5.5 Other Types
    • 5.5.1 Atypical Autism
    • 5.5.2 Childhood Disintegrative Disorder
    • 5.5.3 PDD-NOS

6 Global Autism Spectrum Disorder Diagnostics Market, By Diagnostic Method

  • 6.1 Introduction
  • 6.2 Behavioral Assessments
  • 6.3 Genetic Testing
  • 6.4 Neuroimaging Techniques
  • 6.5 Biomarker Analysis
  • 6.6 Developmental Screening
  • 6.7 Cognitive Assessment
  • 6.8 Neurological Assessment

7 Global Autism Spectrum Disorder Diagnostics Market, By Service

  • 7.1 Introduction
  • 7.2 Clinical Assessments
  • 7.3 Standardized Screening Tools
  • 7.4 Digital Assessment Tools
  • 7.5 Neuropsychological Tests
  • 7.6 Behavioral Approaches
  • 7.7 Early Intervention
  • 7.8 Medication
  • 7.9 Telehealth Services
  • 7.10 Other Services

8 Global Autism Spectrum Disorder Diagnostics Market, By Age Group

  • 8.1 Introduction
  • 8.2 Children (Pediatric)
  • 8.3 Adolescents
  • 8.4 Adults

9 Global Autism Spectrum Disorder Diagnostics Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Drug Stores and Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Autism Spectrum Disorder Diagnostics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Diagnostic Centers
  • 10.4 Research Institutes
  • 10.5 Specialty Clinics
  • 10.6 Educational Institutions

11 Global Autism Spectrum Disorder Diagnostics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Agilent Technologies Inc.
  • 13.2 F. Hoffmann-La Roche Ltd.
  • 13.3 Abbott Laboratories
  • 13.4 Cognoa Inc.
  • 13.5 Thermo Fisher Scientific Inc.
  • 13.6 Siemens Healthineers
  • 13.7 Invitae Corporation
  • 13.8 GE Healthcare
  • 13.9 Illumina, Inc.
  • 13.10 GeneDx
  • 13.11 PerkinElmer, Inc.
  • 13.12 Fulgent Genetics
  • 13.13 Charles River Laboratories International, Inc.
  • 13.14 Myriad Genetics, Inc.
  • 13.15 Cortica Inc.

List of Tables

  • Table 1 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Autistic Disorder (2024-2032) ($MN)
  • Table 4 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Asperger Syndrome (2024-2032) ($MN)
  • Table 5 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Pervasive Development Disorder (PDD) (2024-2032) ($MN)
  • Table 6 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 7 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Atypical Autism (2024-2032) ($MN)
  • Table 8 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Childhood Disintegrative Disorder (2024-2032) ($MN)
  • Table 9 Global Autism Spectrum Disorder Diagnostics Market Outlook, By PDD-NOS (2024-2032) ($MN)
  • Table 10 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Diagnostic Method (2024-2032) ($MN)
  • Table 11 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Behavioral Assessments (2024-2032) ($MN)
  • Table 12 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Genetic Testing (2024-2032) ($MN)
  • Table 13 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Neuroimaging Techniques (2024-2032) ($MN)
  • Table 14 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Biomarker Analysis (2024-2032) ($MN)
  • Table 15 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Developmental Screening (2024-2032) ($MN)
  • Table 16 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Cognitive Assessment (2024-2032) ($MN)
  • Table 17 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Neurological Assessment (2024-2032) ($MN)
  • Table 18 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Service (2024-2032) ($MN)
  • Table 19 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Clinical Assessments (2024-2032) ($MN)
  • Table 20 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Standardized Screening Tools (2024-2032) ($MN)
  • Table 21 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Digital Assessment Tools (2024-2032) ($MN)
  • Table 22 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Neuropsychological Tests (2024-2032) ($MN)
  • Table 23 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Behavioral Approaches (2024-2032) ($MN)
  • Table 24 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Early Intervention (2024-2032) ($MN)
  • Table 25 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Medication (2024-2032) ($MN)
  • Table 26 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Telehealth Services (2024-2032) ($MN)
  • Table 27 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Other Services (2024-2032) ($MN)
  • Table 28 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Age Group (2024-2032) ($MN)
  • Table 29 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Children (Pediatric) (2024-2032) ($MN)
  • Table 30 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Adolescents (2024-2032) ($MN)
  • Table 31 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Adults (2024-2032) ($MN)
  • Table 32 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 33 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 34 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Drug Stores and Retail Pharmacies (2024-2032) ($MN)
  • Table 35 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 36 Global Autism Spectrum Disorder Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 37 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 38 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 39 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 40 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 41 Global Autism Spectrum Disorder Diagnostics Market Outlook, By Educational Institutions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.